Transcode Therapeutics, Inc. (RNAZ)
About Transcode Therapeutics, Inc.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$34.7M
- Total assets
- $162.4M
- Market cap
- $5.3M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $28.0M
- Operating income
- -$28.0M
- Income tax
- $226.1K
- Net income
- -$34.7M
- EPS (basic)
- $-52.59
- EPS (diluted)
- $-52.59
Balance sheet
- Total assets
- $162.4M
- Current assets
- $22.0M
- Total liabilities
- $10.5M
- Current liabilities
- $3.5M
- Shareholders’ equity
- $10.3M
Cash flow
- Operating cash flow
- -$19.5M
- Investing cash flow
- -$4.4K
- Financing cash flow
- $31.5M
- Net cash flow
- $12.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $5.3M
- EPS (diluted)
- $-52.59
- Shares outstanding
- 897.4K
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 9, 2021
Transcode Therapeutics, Inc. (RNAZ) Stock Price
- Reported a net loss of $34.7M.
- Trading 61% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Transcode Therapeutics, Inc..
Write a review
News about Transcode Therapeutics, Inc.
News & sentiment via Polygon.io
Transcode Therapeutics, Inc.: frequently asked questions
Is Transcode Therapeutics, Inc. an American company?
Transcode Therapeutics, Inc. is a US-based company headquartered in Boston, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Transcode Therapeutics, Inc. headquartered?
Transcode Therapeutics, Inc. is headquartered in Boston, Massachusetts, United States.
Is Transcode Therapeutics, Inc. publicly traded?
Yes — Transcode Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol RNAZ on the NASDAQ.
What does Transcode Therapeutics, Inc. do?
Transcode Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
